Nikkei 225
Eisai
Eisai is a major Japanese drugmaker known for the Alzheimer's treatment Leqembi. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
4523.T Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-22.9%'22+42.2%'23-10.9%'24-32.2%'25-3.5%YTD+1.3%
Money in ▸·
Eisai~¥740B
▸ Money out·
Financials & Segments
- Total revenue · ~¥740B (FY2024)
- Segments · Neurology (dementia) · Oncology · Other pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.